An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study

(2021) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature

(2021) Simone Meini et al.   INFECTION

Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors

(2021) Milo Gatti et al.   Expert Review of Clinical Pharmacology

Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

(2020) Renee Ackley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

(2020) Sara Alosaimy et al.   Open Forum Infectious Diseases

Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales

(2020) Marco Falcone et al.   CLINICAL INFECTIOUS DISEASES

Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017

(2020) Jean-Louis Vincent et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

(2020) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae

(2020) Buket Erturk Sengel et al.   JOURNAL OF CHEMOTHERAPY

Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline

(2020) Sara E Boyd et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria

(2020) Shazad Mushtaq et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

(2020) Naoki Kohira et al.   Journal of Global Antimicrobial Resistance

Treatment of invasive IMP‐4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review

(2020) Kelly A. Cairns et al.   Transplant Infectious Disease

Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?

(2020) Paola Bocanegra-Ibarias et al.   Journal of Global Antimicrobial Resistance

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data

(2020) Daniele Roberto Giacobbe et al.   Infection and Drug Resistance

Rationalizing antimicrobial therapy in the ICU: a narrative review

(2019) Jean-François Timsit et al.   INTENSIVE CARE MEDICINE

Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections

(2019) Jesús Rodríguez-Baño et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

AmpC β-lactamase-producing Enterobacterales: what a clinician should know

(2019) Simone Meini et al.   INFECTION

Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment

(2019) Milo Gatti et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa

(2019) Benoît Pilmis et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam

(2019) Matthaios Papadimitriou-Olivgeris et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae

(2019) Carlota Gudiol et al.   Current Opinion in Critical Care

Co-Infections of Two Strains of NDM-1 and OXA-232 Co-producing Klebsiella pneumoniae in a Kidney Transplant Patient

(2019) Deisy A. Contreras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae

(2019) Basem M. Alraddadi et al.   BMC INFECTIOUS DISEASES

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

(2019) Johann Motsch et al.   CLINICAL INFECTIOUS DISEASES

EFFICACY OF CEFTAZIDIME-AVIBACTAM IN MONOTHERAPY OR COMBINATION THERAPY AGAINST CARBAPENEM RESISTANT GRAM NEGATIVE ORGANISMS: A META-ANALYSIS

(2019) Lorenzo Onorato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections

(2019) Ryan K Shields et al.   CLINICAL INFECTIOUS DISEASES

The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review

(2019) Abrar K. Thabit et al.   CLINICAL THERAPEUTICS

Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases

(2019) Laura Benchetrit et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase–4 and New Delhi Metallo-β-Lactamase–1

(2019) Mohamad Yasmin et al.   CLINICAL INFECTIOUS DISEASES

Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms?

(2019) Sima L Sharara et al.   CLINICAL INFECTIOUS DISEASES

Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia

(2019) David L. Paterson et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems

(2019) Sock Hoon Tan et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam

(2019) Elske Sieswerda et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae

(2018) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials

(2018) Mengmeng Chen et al.   Expert Review of Anti-Infective Therapy

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

(2018) Konstantinos Z Vardakas et al.   LANCET INFECTIOUS DISEASES

Treatment of Infections with OXA-48 producing Enterobacteriaceae

(2018) Adam Stewart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Beta-lactam/ beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended spectrum beta-lactamase producing Enterobacteriaceae : Systematic review and meta-analysis

(2018) Maroun Sfeir et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance

(2018) Patrick N. A. Harris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Carbapenem versus Cefepime or Piperacillin-Tazobactam for the Empiric Treatment of Extended Spectrum β-lactamase Producing Escherichia coli Bacteremia in Patients with Hematologic Malignancy

(2018) Grace E. Benanti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

(2018) Michael R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful treatment of a bacteremia due to NDM-1-producing Morganella morganii with Aztreonam and Ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy

(2018) Claire Amaris Hobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM

(2018) C. De la Calle et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

(2017) J. Dobias et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study

(2017) J.-H. Ko et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

(2017) Andrew Rhodes et al.   INTENSIVE CARE MEDICINE

Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli

(2017) Young Kyung Yoon et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

(2017) Juan J. Castón et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection

(2017) Evelyn Shaw et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

(2016) Belén Gutiérrez-Gutiérrez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program

(2016) Elizabeth Temkin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study

(2016) Belén Gutiérrez-Gutiérrez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

Antimicrobial Resistance in the Intensive Care Unit

(2016) Shawn H. MacVane   JOURNAL OF INTENSIVE CARE MEDICINE

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

(2016) Tat Ming Ng et al.   PLoS One

Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates

(2015) Nan-Yao Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum  -Lactamase Bacteremia

(2015) P. D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

(2015) Hadas Ofer-Friedman et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review

(2015) Verónica Seija et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project

(2015) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysis

(2015) Patrick N. A. Harris et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae

(2015) Patrick N A Harris et al.   Antimicrobial Resistance and Infection Control

Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia

(2014) M. J. Siedner et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials

(2014) Abrar K Thabit et al.   EXPERT OPINION ON PHARMACOTHERAPY

Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012

(2014) Kirsi-Maija Kaukonen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

(2014) Lisa M. Blanchette et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae

(2013) Pranita D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011)

(2013) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?

(2013) Markus Hilty et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Severe Sepsis and Septic Shock

(2013) Derek C. Angus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

(2012) Vicki L. Collins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae

(2012) Cheol-In Kang et al.   JOURNAL OF INFECTION

Comparison of Ertapenem and Ceftriaxone Therapy for Acute Pyelonephritis and Other Complicated Urinary Tract Infections in Korean Adults: A Randomized, Double-Blind, Multicenter Trial

(2012) Dae Won Park et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

 -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum  -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts

(2011) J. Rodriguez-Bano et al.   CLINICAL INFECTIOUS DISEASES

Appropriateness is Critical

(2010) Marta Ulldemolins et al.   CRITICAL CARE CLINICS

Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock

(2009) Anand Kumar et al.   CHEST

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES